Trial Profile

A Phase 3 Study to Evaluate LL-BMT1 for the Treatment of Glaucoma or Ocular Hypertension

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimatoprost (Primary)
Indications Glaucoma; Ocular hypertension
Focus Registrational; Therapeutic Use
Acronyms SIGHT-3
Sponsors MediPrint Ophthalmics

Most Recent Events

06 Feb 2025 According to MediPrint Opthalmics media release, The company expects to engage with the FDA in 2025 to align regulatory requirements and define the pathway for Phase 3 studies.
23 Mar 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com